Page last updated: 2024-12-07
proxodolol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
proxodolol: structure given in first source (3-methoxy- instead of 3-methyl-; text of article gives name as 3-methyl-; see also article on page 27 of the same source) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 133047 |
| MeSH ID | M0234576 |
Synonyms (11)
| Synonym |
|---|
| proxodolol |
| 1-(tert-butylamino)-3-[2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy]propan-2-ol |
| unii-95n3wb936t |
| (+/-)-1-(2-((3-methoxy-1,2,4-oxadiazol-5-yl)methoxy)phenoxy)-3-((tert-butylamino))propan-2-ol |
| zoleprodolol [inn] |
| 158599-53-2 |
| 95n3wb936t , |
| zoleprodolol |
| (+/-)-1-(2-((3-methoxy-1,2,4-oxadiazol-5-yl)methoxy)phenoxy)-3-(tert-butylamino)propan-2-ol |
| Q27271805 |
| AKOS040754576 |
Research Excerpts
Toxicity
Proxodolol is effective and safe in hypertension. In a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH." | ( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree]. Beliaeva, SA, 2011) | 0.37 |
| "Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg." | ( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree]. Beliaeva, SA, 2011) | 0.37 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH)." | ( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree]. Beliaeva, SA, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (44.44%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (55.56%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||